Location: South San Francisco, Calif.

R&D Focus: Using gene editing to eliminate viral DNA in latent or persistent viral reservoirs to treat viral diseases, including HPV, cytomegalovirus (CMV), Epstein Barr virus and hepatitis B

Founding Date: Launched in 2016

Founders: Stanford University bioengineering and applied physics professor Stephen Quake, life science consultant Bruce Hironaka, professor Angela Wu of Hong Kong University of Science and Technology (formerly Stanford) and professor Jianbin Wang from the School of Life Sciences at Tsinghua University (formerly Stanford)

Employees: 15 with plans to grow to 30

Financing To Date: $10.6m Series A in May 2016

Investors: Data Collective, Celgene Corp., Lightspeed Venture Partners and other individuals and private investors

Agenovir: Using Gene Editing To Kill Viral DNA

More from Start-Ups & SMEs

More from Business